Purpose: To make a prospective investigation of toxicity, functional and oncological outcome, and quality of life (QoL) in pts with locally advanced rectal cancer given intensive preoperative radio-chemotherapy (RTCT). Methods: From May 2000 to April 2002, 44 TNM stage II-III mid-low rectal cancer pts (mean age: 58 yrs, range: 35-74; M/F: 25/19) enrolled in a multicentric prospective phase I-II study were given RTCT (50.4 Gy/28E 5FU: 200-225mg/m2/day CI and weekly Oxaliplatin, 25-60 rag/m2) followed, 4 to 6 weeks later, by surgery. In 22 pts in a single surgical unit, anorectal function and QoL were investigated using the fecal incontinence scoring system (FISS) and EORTC QLQ-CR38 questionnaire, administered before RT (tO), preoperatively (tl), and one year after surgery (t2). Statistical analysis: Kaplan-Meier curves for overall (OS) and disease-free survival (DFS); repeated measures analysis of variance for differences in scores over time. Results: Acute grade 3+ toxicity was observed in 8 pts; both sphincter-saving procedure and radical resection were performed in 39 cases. There were no operative deaths; major postoperative complications (anastomotic leak, n=5; hemoperitoneum, n = 1) occurred in 6 pts, of whom 4 required re-operation. Late complications requiring re-admission occurred in 13 patients, of whom 6 required surgery. Twelve (27%) pts had a pathological complete response (pCR). At a median follow-up of 20 months, 4 pts had recurrence and 3 died. A not significant worsening in FISS was observed: median score of 25, 25, and 62, for time tO, tl, and t2, respectively. Out of the parameters investigated using QLQ-CR38, only "future perspective" showed significant improvement over time (mean score: 33, 43 and 54). Actuarial OS and DFS at 30 months were 93 and 88%, respectively. Conclusion: Following this new aggressive RTCT preoperative regimen used by us, pCR, short-term oncological results, QoL and intestinal function observed appear to be promising, although drug toxicity and late post-surgical complications are not negligible P100 mTOR signaling is a possible new biochemical target for pancreatic cancer therapy Mismatch repair defective colorectal cancers, colurnonly characterised by loss of hMLH 1 expression not only have a stage-matched improved prognosis over hMLH1 positive tumours but are also less likely to metastasise. The reason for this is unclear. The MMP family of enzymes facilitate tumour invasion and metatasis with increased MMP 1, MMP9 and MMP 13 expression being associated with significantly shorter disease-free survival in CRC. MMP 12 has been correlated with an improved prognosis. The aim of this study was to ascertain if the observed differences in survival were related to gene silencing in hMLH1 deficient tumours. Ninety-six right-sided cancers (6 SSO 57TH ANNUAL CANCER SYMPOSIUM $113
Introduction: The mammalian target of rapamycin (mTOR) plays a central role in the cell proliferation through the regulation of cell cycle. Dysregulation of mTOR signaling occurs in diverse hmnan tumors, and can confer higher susceptibility to inhibitors ofmTOR. In this study, we investigated whether the mTOR signaling is activated in 6 pancreatic cancer cell lines and tissue specimens of pancreatic ductal adenocarcinoma (PDA), and examined antiproliferative effects of the mTOR inhibitor, CCI-779. Methods: First, we examined the expression pattern of PTEN, phospho-Akt (AKT), p-mTOR (mTOR) and p-p70S6K (p70S6K) in 6 human pancreatic cancer cell lines and 20 tissue specimens of PDA by western blot and immunohistochemistry. Next, we examined the cytotoxicity of the mTOR inhibitor, in the 6 cell lines in vitro as single agent and in combination with standard chemotherapeutic drug, gemcitabine (10 nM). Finally, the antitumor effects of CCI-779 were examined using in AsPC-1 and Suit-2 xenograft models. Results: As shown in the table below, on a panel of 6 pancreatic cancer cell lines, PTEN expression was detected in 4 cell lines except for KMP-3 and KMP-4 cells. Interestingly, Akt was strongly phosphorylated even in the 4 cell lines which showed the positive expression of PTEN. mTOR and p70S6K were activated in all of the 6 cell lines examined. In the tissue specimens of PDA, p-Akt expression was detected in 60% of the specimens, p-mTOR was detected 55%, and p-p70S6K was detected in 45%. With respect to the growth inhibitory effects of CCI-779, AsPC-1 and KMP-3 cells were highly sensitive to the treatment, and BxPC-3 and Suit-2 cells were slightly resistant. Intriguingly, CCI-779 had additive effects with gemcitabine in the 2 cell lines resistant to the treatment with CCI-779 alone such as BxPC-3 and Suit-2. Furthermore, CCI-779 induced antitumor activity in both of AsPC-1 (sensitive in vitro) and Suit-2 (resistant in vitro) xenografts. Conclusions: These results suggest that roTOR may be a good target for pancreatic cancer therapy and the roTOR inhibitor, CCI-779 is an important new agent to investigate in the treatment of pancreatic cancer.
Expression of roTOR signaling and effect of CCI-779 on the growth of human pancreatic cancer eel) lines. Introduction: The use of self expandable metallic stents in the management of obstructing colorectal cancer has been described with increasing frequency in the literature. Radiological and endoscopic techniques have been described as a bridge to surgery (bowel preparation and performing a onestage procedure) and for palliation. In order to determine the role of stents, the efficacy in the relief of colorectal obsmaction and the morbidity of this procedure must be known. Methods: A retrospective chart review of patients undergoing colorectal stent placement between December 2001 and August 2003 was performed. Results: Stent placement was attempted in 21 patients with coloreetal obstruction. Technical success was achieved in 17 (81%) patients. Stents were placed endoscopically in 12 patients and radiologically in 5 patients. The locations of obstruction were the sigmoid colon (14/17 patients), the splenic flexure, the hepatic flexure, and rectum. 10 stents were placed as a bridge to surgery and 7 stents were placed for palliation. Malignant obstruction was noted in 16/17 patients. Early complications related to stent placement occurred in one patient, (1/17 patients, 6%), who experienced a sigmoid perforation 4 days after stent insertion. 6 patients who had a stent placed for palliation secondary to malignant obstruction were free from stent related problems in the follow up period (5-14 months). One patient who had a stent placed to relieve a benign obstructing sigmoid stricture had occlusion of her stent 4 months post-placement. Stent patency in obstruction secondary to colonic adenocarcinoma was 100% in our follow-up period. Conclusions: The use of stents as a bridge to surgery is associated with low morbidity and serves to avoid the need for a temporary colostomy. Their excellent patency suggests that stents may allow for the avoidance of an operation and further defines their role in the palliation of malignant obstruction. Further study is necessary to fully elucidate the use of stents in the management of colorectal cancer.
